UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 31, 2009
Neurologix, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 000-13347 | 06-1582875 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| One Bridge Plaza, Fort Lee,
New Jersey |
07024 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (201) 592-6451
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement
Neurologix, Inc. (the
“Company”) entered into a letter agreement (the “Letter
Agreement”) dated August 31, 2009 with Dr. Matthew
During. The Letter Agreement amends a Consulting Agreement dated
October 1, 1999, as amended (the “Consulting Agreement”), by
and between the Company and Dr. During. The Letter Agreement
extends the term of the Consulting Agreement from September 30, 2009 to
September 30, 2010. Dr. During is a co-founder of the
Company and a member of its Scientific Advisory Board.
A copy
of the Letter Agreement is attached hereto as Exhibit 10.1 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
10.1 Letter Agreement dated August 31, 2009 between Neurologix, Inc. and Dr. Matthew During.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto, duly authorized.
| NEUROLOGIX, INC. | ||||
|
|
||||
|
|
||||
|
Date: August 31, 2009
|
By: | /s/ Marc L. Panoff | ||
|
|
||||
|
|
Name: | Marc L. Panoff | ||
|
|
Title: | Chief Financial Officer, Secretary and Treasurer | ||
|
|
||||